Of note, ongoing studies in our lab have shown potential for inhibition of SHP2, which functions upstream of RAS, to enhance the effectiveness of JAK2 inhibition in pre-clinical MPN models [82]. Here, JAK2 is linked to myeloproliferative neoplasm.